G. Walmsley Graham, Director at Akero Therapeutics, Inc. (AKRO), bought 25,000 shares at $42.06 ($1.1M) on 2023-08-08, disclosed to the SEC on 2023-08-10.
Open-market purchase of $1.1M AKRO by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| OLMA | SELL | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-18 | $9.5M | — | Filing → |
| OLMA | BUY | 2024-12-17 | $4.7M | — | Filing → |